Related Experiment Video

Updated: Jul 17, 2026

Patch Angioplasty in the Rat Aorta or Inferior Vena Cava
06:04

Patch Angioplasty in the Rat Aorta or Inferior Vena Cava

Published on: February 27, 2017

Treatment of patent ductus arteriosus with ibuprofen

B Van Overmeire1, I Follens, S Hartmann

  • 1Department of Paediatrics, University Hospital of Antwerp, Belgium.

Archives of Disease in Childhood. Fetal and Neonatal Edition
|May 1, 1997
PubMed

Insights

Ibuprofen is as effective as indomethacin for closing patent ductus arteriosus (PDA) in preterm infants. Ibuprofen demonstrated fewer renal side effects, offering a potentially safer early treatment option for respiratory distress syndrome.

Area of Science:

  • Neonatalogy
  • Pharmacology
  • Pediatric Cardiology

Background:

  • Patent ductus arteriosus (PDA) is a common complication in preterm infants, particularly those with respiratory distress syndrome (RDS).
  • Early pharmacological intervention is crucial for managing PDA and preventing associated morbidities.

Purpose of the Study:

  • To compare the efficacy and safety of early ibuprofen treatment versus indomethacin for PDA closure in preterm infants.
  • To evaluate potential differences in renal side effects between the two treatments.

Main Methods:

  • A randomized trial involving 40 preterm infants (gestational age < 33 weeks) with confirmed PDA and RDS.
  • Infants received either intravenous indomethacin (3 doses) or a single high dose of intravenous ibuprofen followed by two lower doses.

Main Results:

  • PDA closure rates were similar: 75% with indomethacin and 80% with ibuprofen.
  • Ibuprofen group showed improved urinary output and no significant increase in serum creatinine.
  • Fewer infants in the ibuprofen group required a second treatment or surgical ligation.

Conclusions:

  • Ibuprofen is a viable and effective alternative to indomethacin for early PDA treatment in preterm infants with RDS.
  • Ibuprofen appears to have a favorable renal safety profile compared to indomethacin.
Abstract

More Related Videos

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence10:52

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence

Published on: December 23, 2022

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...